Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment
| Autor: | Ava B. Plummer, Morris D. Groves |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Neurosurgical Procedures Internal medicine Temozolomide medicine Humans Risks and benefits Practice Patterns Physicians' Duration (project management) Antineoplastic Agents Alkylating Genetics (clinical) Physician-Patient Relations Chemotherapy Radiotherapy Brain Neoplasms business.industry Middle Aged medicine.disease Combined Modality Therapy Dacarbazine Radiation therapy Female Neurology (clinical) Glioblastoma business Adjuvant medicine.drug |
| Zdroj: | CONTINUUM: Lifelong Learning in Neurology. 18:421-425 |
| ISSN: | 1080-2371 |
| Popis: | Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|